Loqtorzi (toripalimab)
- Region
- 🇪🇺 EU
- Active substance
- toripalimab
- Company
- Topalliance Biosciences Europe Limited
- Status
- Authorised
- Therapeutic area
- Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma
- CHMP opinion
- Thu 25 Jul 2024
- EU approval
- Thu 19 Sep 2024
- Designations
- Additional monitoring
- Application
- EMEA/H/C/006120
- ATC
- L01FF13
- Official record
- www.ema.europa.eu
Indication
Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Regulatory milestones
No milestones recorded in the last year.
Follow Loqtorzi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.